ALVO
Alvotech
Drug Manufacturers - Specialty & Generic
Market Cap$999M
5Y Perf.-61.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ALVO vs TEVA
Revenue, margins, valuation, and 5-year total return — side by side.
TEVA
Teva Pharmaceutical Industries Limited
Drug Manufacturers - Specialty & Generic
Market Cap$41.93B
5Y Perf.+378.9%
ALVO vs TEVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ALVO | TEVA |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $999M | $41.93B |
| Revenue (TTM) | $586M | $17.35B |
| Net Income (TTM) | $28M | $1.56B |
| Gross Margin | 59.8% | 52.1% |
| Operating Margin | 13.3% | 13.2% |
| Forward P/E | 100.9x | 14.5x |
| Total Debt | $1.45B | $17.38B |
| Cash & Equiv. | $172M | $3.56B |
ALVO vs TEVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ALVO
TEVA
| Stock | Jun 22 | May 26 | Return |
|---|---|---|---|
| Alvotech (ALVO) | 100 | 39.0 | -61.0% |
| Teva Pharmaceutical… (TEVA) | 100 | 478.9 | +378.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ALVO vs TEVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TEVA leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Alvotech is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
ALVO
Alvotech
The Income Pick
ALVO is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.11
- Rev growth 19.7%, EPS growth 111.5%, 3Y rev CAGR 91.9%
- Lower volatility, beta 1.11, current ratio 1.89x
Best for: income & stability and growth exposure
TEVA
Teva Pharmaceutical Industries Limited
The Long-Run Compounder
TEVA carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -28.3% 10Y total return vs ALVO's -71.4%
- Lower P/E (14.5x vs 100.9x)
- 9.0% margin vs ALVO's 4.8%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ALVO | 19.7% revenue growth vs TEVA's 4.3% |
| Value | TEVA | Lower P/E (14.5x vs 100.9x) |
| Quality / Margins | TEVA | 9.0% margin vs ALVO's 4.8% |
| Stability / Safety | ALVO | Beta 1.11 vs TEVA's 1.13 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TEVA | +104.6% vs ALVO's -59.7% |
| Efficiency (ROA) | TEVA | 3.9% ROA vs ALVO's 2.0%, ROIC 7.7% vs 6.8% |
ALVO vs TEVA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2023
FY 2025
ALVO vs TEVA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTEVALAGGINGALVO
ALVOAlvotech
0leads
TEVATeva Pharmaceutical I…
3leads
6 Total Categories
CATEGORYLEADERvs ALVOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
TEVA3/4
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TEVA5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
TEVA6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — ALVO and TEVA each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TEVA is the larger business by revenue, generating $17.3B annually — 29.6x ALVO's $586M. Profitability is closely matched — net margins range from 9.0% (TEVA) to 4.8% (ALVO). On growth, ALVO holds the edge at +10.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ALVOAlvotech | TEVATeva Pharmaceutic… |
|---|---|---|
| RevenueTrailing 12 months | $586M | $17.3B |
| EBITDAEarnings before interest/tax | $78M | $3.3B |
| Net IncomeAfter-tax profit | $28M | $1.6B |
| Free Cash FlowCash after capex | -$115M | $1.2B |
| Gross MarginGross profit ÷ Revenue | +59.8% | +52.1% |
| Operating MarginEBIT ÷ Revenue | +13.3% | +13.2% |
| Net MarginNet income ÷ Revenue | +4.8% | +9.0% |
| FCF MarginFCF ÷ Revenue | -19.6% | +6.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +10.0% | +2.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -95.5% | +72.2% |
Evenly matched — ALVO and TEVA each lead in 3 of 6 comparable metrics.
Valuation Metrics
TEVA leads this category, winning 3 of 4 comparable metrics.
Valuation Metrics
At 30.0x trailing earnings, TEVA trades at a 6% valuation discount to ALVO's 32.0x P/E. On an enterprise value basis, TEVA's 17.6x EV/EBITDA is more attractive than ALVO's 19.6x.
| Metric | ALVOAlvotech | TEVATeva Pharmaceutic… |
|---|---|---|
| Market CapShares × price | $999M | $41.9B |
| Enterprise ValueMkt cap + debt − cash | $2.3B | $55.8B |
| Trailing P/EPrice ÷ TTM EPS | 32.00x | 30.01x |
| Forward P/EPrice ÷ next-FY EPS est. | 100.95x | 14.55x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 19.61x | 17.65x |
| Price / SalesMarket cap ÷ Revenue | 1.70x | 2.43x |
| Price / BookPrice ÷ Book value/share | — | 5.34x |
| Price / FCFMarket cap ÷ FCF | — | 36.52x |
TEVA leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
TEVA leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), TEVA scores 8/9 vs ALVO's 3/9, reflecting strong financial health.
| Metric | ALVOAlvotech | TEVATeva Pharmaceutic… |
|---|---|---|
| ROE (TTM)Return on equity | — | +20.7% |
| ROA (TTM)Return on assets | +2.0% | +3.9% |
| ROICReturn on invested capital | +6.8% | +7.7% |
| ROCEReturn on capital employed | +7.1% | +8.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 8 |
| Debt / EquityFinancial leverage | — | 2.20x |
| Net DebtTotal debt minus cash | $1.3B | $13.8B |
| Cash & Equiv.Liquid assets | $172M | $3.6B |
| Total DebtShort + long-term debt | $1.4B | $17.4B |
| Interest CoverageEBIT ÷ Interest expense | 0.52x | 2.51x |
TEVA leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
TEVA leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TEVA five years ago would be worth $34,625 today (with dividends reinvested), compared to $2,860 for ALVO. Over the past 12 months, TEVA leads with a +104.6% total return vs ALVO's -59.7%. The 3-year compound annual growth rate (CAGR) favors TEVA at 58.4% vs ALVO's -30.4% — a key indicator of consistent wealth creation.
| Metric | ALVOAlvotech | TEVATeva Pharmaceutic… |
|---|---|---|
| YTD ReturnYear-to-date | -36.0% | +16.3% |
| 1-Year ReturnPast 12 months | -59.7% | +104.6% |
| 3-Year ReturnCumulative with dividends | -66.3% | +297.5% |
| 5-Year ReturnCumulative with dividends | -71.4% | +246.2% |
| 10-Year ReturnCumulative with dividends | -71.4% | -28.3% |
| CAGR (3Y)Annualised 3-year return | -30.4% | +58.4% |
TEVA leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ALVO and TEVA each lead in 1 of 2 comparable metrics.
Risk & Volatility
ALVO is the less volatile stock with a 1.11 beta — it tends to amplify market swings less than TEVA's 1.13 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TEVA currently trades 96.4% from its 52-week high vs ALVO's 27.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ALVOAlvotech | TEVATeva Pharmaceutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.11x | 1.13x |
| 52-Week HighHighest price in past year | $11.85 | $37.35 |
| 52-Week LowLowest price in past year | $3.03 | $14.99 |
| % of 52W HighCurrent price vs 52-week peak | +27.0% | +96.4% |
| RSI (14)Momentum oscillator 0–100 | 51.5 | 73.5 |
| Avg Volume (50D)Average daily shares traded | 510K | 6.6M |
Evenly matched — ALVO and TEVA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ALVO as "Buy" and TEVA as "Buy". Consensus price targets imply 168.7% upside for ALVO (target: $9) vs 8.3% for TEVA (target: $39).
| Metric | ALVOAlvotech | TEVATeva Pharmaceutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $8.60 | $39.00 |
| # AnalystsCovering analysts | 5 | 46 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
TEVA leads in 3 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency. 2 categories are tied.
Best OverallTeva Pharmaceutical Industr… (TEVA)Leads 3 of 6 categories
Loading custom metrics...
ALVO vs TEVA: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is ALVO or TEVA a better buy right now?
For growth investors, Alvotech (ALVO) is the stronger pick with 19.
7% revenue growth year-over-year, versus 4. 3% for Teva Pharmaceutical Industries Limited (TEVA). Teva Pharmaceutical Industries Limited (TEVA) offers the better valuation at 30. 0x trailing P/E (14. 5x forward), making it the more compelling value choice. Analysts rate Alvotech (ALVO) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ALVO or TEVA?
On trailing P/E, Teva Pharmaceutical Industries Limited (TEVA) is the cheapest at 30.
0x versus Alvotech at 32. 0x. On forward P/E, Teva Pharmaceutical Industries Limited is actually cheaper at 14. 5x.
03Which is the better long-term investment — ALVO or TEVA?
Over the past 5 years, Teva Pharmaceutical Industries Limited (TEVA) delivered a total return of +246.
2%, compared to -71. 4% for Alvotech (ALVO). Over 10 years, the gap is even starker: TEVA returned -28. 3% versus ALVO's -71. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ALVO or TEVA?
By beta (market sensitivity over 5 years), Alvotech (ALVO) is the lower-risk stock at 1.
11β versus Teva Pharmaceutical Industries Limited's 1. 13β — meaning TEVA is approximately 2% more volatile than ALVO relative to the S&P 500.
05Which is growing faster — ALVO or TEVA?
By revenue growth (latest reported year), Alvotech (ALVO) is pulling ahead at 19.
7% versus 4. 3% for Teva Pharmaceutical Industries Limited (TEVA). On earnings-per-share growth, the picture is similar: Teva Pharmaceutical Industries Limited grew EPS 182. 8% year-over-year, compared to 111. 5% for Alvotech. Over a 3-year CAGR, ALVO leads at 91. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ALVO or TEVA?
Teva Pharmaceutical Industries Limited (TEVA) is the more profitable company, earning 8.
2% net margin versus 4. 8% for Alvotech — meaning it keeps 8. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALVO leads at 13. 3% versus 12. 5% for TEVA. At the gross margin level — before operating expenses — ALVO leads at 59. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ALVO or TEVA more undervalued right now?
On forward earnings alone, Teva Pharmaceutical Industries Limited (TEVA) trades at 14.
5x forward P/E versus 100. 9x for Alvotech — 86. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALVO: 168. 7% to $8. 60.
08Which pays a better dividend — ALVO or TEVA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is ALVO or TEVA better for a retirement portfolio?
For long-horizon retirement investors, Teva Pharmaceutical Industries Limited (TEVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
13)). Both have compounded well over 10 years (TEVA: -28. 3%, ALVO: -71. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ALVO and TEVA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ALVO is a small-cap high-growth stock; TEVA is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(ALVO: 10.0% · TEVA: 2.3%)Net Margin>
%
(ALVO: 4.8% · TEVA: 9.0%)P/E Ratio<
x
(ALVO: 32.0x · TEVA: 30.0x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.